Borderline ovarian tumour after fertility sparing surgery for ovarian cancer

Borderline ovarian tumours are an intermediate entity between benign and malignant epithelial ovarian neoplasms. The authors present the case of a 25-year-old patient, with a history of fertility-preserving right salpingo-oophorectomy due to an ovarian serous papillary cystadenocarcinoma six years ago. The patient recently presented with a cyst in the left ovary which raised concerns for recurrent disease. The patient underwent a left ovarian cystectomy and the histopathological examination concluded in serous borderline tumour. The patient is followed up regularly, so that a possible relapse will be diagnosed in time. In conclusion, a borderline lesion in the remaining ovary, after ovarian conservative surgery, is a challenge that could represent either a de novo emergence of borderline tumour or possibly the onset of a new ovarian cancer. The study of early molecular alterations could be a promising tool in the investigation of prognosis and management of these lesions.

Borderline ovarian tumour; Recurrent ovarian disease; Fertility sparing; Ovarian cystectomy.

[1] Fischerova D., Zikan M., Dundr P., Cibula D.: “Diagnosis, treatment, and follow-up of borderline ovarian tumors”. Oncologist, 2012, 17, 1515.

[2] Seong S.J., Kim da H., Kim M.K., Song T.: “Controversies in borderline ovarian tumors”. J. Gynecol. Oncol., 2015, 26, 343.

[3] Cadron I., Leunen K., Van Gorp T., Amant F., Neven P., Vergote I.: “Management of borderline ovarian neoplasms”. J. Clin. Oncol., 2007, 25, 2928.

[4] Fader A.N., Rose P.G.: “Role of surgery in ovarian carcinoma”. J. Clin. Oncol., 2007, 25, 2873.

[5] Schorge J.O., Eisenhauer E.E., Chi D.S.: “Current surgical management of ovarian cancer”. Hematol. Oncol. Clin. North Am., 2012, 26, 93.

[6] Schlaerth A.C., Chi D.S., Poynor E.A., Barakat R.R., Brown C.L.: “Long-term survival after fertility-sparing surgery for epithelial ovarian cancer”. Int. J. Gynecol. Cancer, 2009, 19, 1199.

[7] Schilder J.M., Thompson A.M., DePriest P.D., Ueland F.R., Cibull M.L., Kryscio R.J., et al.: “Outcome of reproductive age women with stage IA or IC invasive epithelial ovarian cancer treated with fertility-sparing therapy”. Gynecol. Oncol., 2002, 87, 1.

[8] Wright J.D., Shah M., Mathew L., Burke W.M., Culhane J., Goldman N., et al.: “Fertility preservation in young women with epithelial ovarian cancer”. Cancer, 2009, 115, 4118.

[9] Zapardiel I., Diestro M.D., Aletti G.: “Conservative treatment of early stage ovarian cancer: oncological and fertility outcomes”. Eur. J. Surg. Oncol., 2014, 40, 387.

[10] Bentivegna E., Morice P., Uzan C., Gouy S.: “Fertility-sparing surgery in epithelial ovarian cancer”. Future Oncol., 2016, 12, 389.

[11] Palomba S., Zupi E., Russo T., Falbo A., Del Negro S., Manguso F., et al.: “Comparison of two fertility-sparing approaches for bilateral borderline ovarian tumours: a randomized controlled study”. Hum. Reprod., 2007, 22, 578.

[12] Vasconcelos I., de Sousa Mendes M.: “Conservative surgery in ovarian borderline tumours: a meta-analysis with emphasis on recurrence risk:. Eur. J. Cancer, 2015, 51, 620.

[13] Letourneau J., Chan J., Salem W., Chan S.W., Shah M., Ebbel E., et al.: “Fertility sparing surgery for localized ovarian cancers maintains an ability to conceive, but is associated with diminished reproductive potential”. J. Surg. Oncol., 2015, 112, 26.

[14] Kajiyama H., Mizuno M., Shibata K., Yamamoto E., Kawai M., Nagasaka T., Kikkawa F.: “Recurrence-predicting prognostic factors for patients with early-stage epithelial ovarian cancer undergoing fertility-sparing surgery: a multi-institutional study”. Eur. J. Obstet. Gynecol. Reprod. Biol., 2014, 175, 97.

[15] du Bois A., Heitz F., Harter P.: “Fertility-sparing surgery in ovarian cancer: a systematic review”. Onkologie, 2013, 36, 436.

[16] Ditto A., Martinelli F., Lorusso D., Haeusler E., Carcangiu M., Raspagliesi F.: “Fertility sparing surgery in early stage epithelial ovarian cancer”. J. Gynecol. Oncol., 2014, 25, 320.

[17] Kajiyama H., Mizuno M., Shibata K., Umezu T., Suzuki S., Yamamoto E., et al.: “Oncologic outcome after recurrence in patients with stage I epithelial ovarian cancer: are clear-cell and mucinous histological types a different entities?” Eur. J. Obstet. Gynecol. Reprod. Biol., 2014, 181, 305.

[18] Della Pepa C., Tonini G., Santini D., Losito S., Pisano C., Di Napoli M., et al.: “Low grade serous ovarian carcinoma: from the molecular characterization to the best therapeutic strategy”. Cancer Treat. Rev., 2015, 41, 136.

[19] Ditto A., Martinelli F., Bogani G., Lorusso D., Carcangiu M., Chiappa V., et al.: “Long-term safety of fertility sparing surgery in early stage ovarian cancer: comparison to standard radical surgical procedures”. Gynecol. Oncol., 2015, 138, 78.

[20] Fruscio R., Corso S., Ceppi L., Garavaglia D., Garbi A., Floriani I., et al.: “Conservative management of early-stage epithelial ovarian cancer: results of a large retrospective series”. Ann. Oncol., 2013, 24, 138.

[21] Girolimetti G., Perrone A.M., Santini D., Barbieri E., Guerra F., Ferrari S., et al.: “BRCA-associated ovarian cancer: from molecular genetics to risk management”. Biomed. Res. Int., 2014, 2014, 787143.

[22] Sun C., Li N., Ding D., Weng D., Meng L., Chen G., Ma D.: “The role of BRCA status on the prognosis of patients with epithelial ovarian cancer: a systematic review of the literature with a meta-analysis”. PLoS One, 2014, 9, e95285.

[23] Bolton K.L., Chenevix-Trench G., Goh C., Sadetzki S., Ramus S.J., Karlan B.Y., et al.: “Association between BRCA1 and BRCA2 mutations and survival in women with invasive epithelial ovarian cancer”. JAMA, 2012, 307, 382.

[24] Kurman R.J., Shih Ie M.: “The origin and pathogenesis of epithelial ovarian cancer: a proposed unifying theory”. Am. J. Surg. Pathol., 2010, 34, 433.

[25] Nezhat F.R., Apostol R., Nezhat C., Pejovic T.: “New insights in the pathophysiology of ovarian cancer and implications for screening and prevention”. Am. J. Obstet. Gynecol., 2015, 213, 262.

[26] Tsang Y.T., Deavers M.T., Sun C.C., Kwan S.Y., Kuo E., Malpica A., et al.: “KRAS (but not BRAF) mutations in ovarian serous borderline tumour are associated with recurrent low-grade serous carcinoma”. J. Pathol., 2013, 231, 449.

[27] Tinelli R., Tinelli A., Tinelli F.G., Cicinelli E., Malvasi A.: “Conservative surgery for borderline ovarian tumors: a review”. Gynecol. Oncol., 2006, 100, 185.